Sally-Ann Turner
Your editor’s letter in a recent issue of HCM raised the question of how the health and fitness industry should respond to the huge growth in the use of weight loss medications (www.hcmmag.com/GLPleader).
With an ever-growing body of evidence showing the benefits, it’s natural to wonder if these weekly injections will disrupt the fitness, health and wellness industry or whether they’ll provide opportunities for growth.
As the operator of medical wellness clinics that have been registered with the Care Quality Commission since 2018, we treat 500 patients a week, supporting them to attain life-changing health results.
Our programmes don’t only focus on weight loss, but also on wider, outcome-driven health targets. We do this by supporting patients on a journey of transformational change, both physically and psychologically and many of our patients are achieving remarkable weight loss on supported weight health programmes that include GLP-1 or GLP-1/GIP medications.
These new medications are not a quick fix and as it states clearly in NICE guidelines – they should always be prescribed alongside support with diet and physical activity.
The market is growing rapidly and even though consumers have the option to get support from the diet and nutrition sector, there’s still a huge gap for fitness and exercise providers to step in to underpin long-term health and wellbeing.
Many of our new patients are considered physically inactive and don’t engage in any form of exercise, meaning there’s demand for fitness programmes not only during their weight loss programme, but also once they’ve reached their goals and are in the maintenance phase of their weight-health journey.
Positive patient outcomes are reliant on long-term behavioural changes in relation to both eating and exercising and this provides opportunities for growth for operators in the health and fitness sector, as well as for powerful collaborations with clinical prescribers and the diet and nutrition sector.
Collectively, we can have an incredible impact on people’s long-term health outcomes, as well as enhancing quality of life for those who are overweight or who have been living with obesity.
NICE guidelines state GLP-1 and GLP-1/GIP medications should always be prescribed alongside support with diet and physical activity